De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects

This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.

A total of 70 patients with HCC (mean age: 54.6 years, female/male: 12/58) received a liver transplant and were included in the study. Immunosuppression included de novo sirolimus, low-dose calcineurin inhibitor for 6 to 12 months, with short-course (3 months) or no steroids.

Inclusion Criteria:

• Adult patients with hepatocellular (HCC) carcinoma receiving liver transplant

Exclusion criteria:

• Patients less than 18 years of age